Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
27 April 2024
| m 08:46 | Non-degenerate nucleotides per response element diffhist +1,634 Marshallsumter talk contribs (→Tabulation of counts) | ||||
| 00:49 | Chronic obstructive pulmonary disease history and symptoms diffhist +2,903 Kosar Doraghi talk contribs | ||||
26 April 2024
|
|
m 20:03 | Non-degenerate nucleotides per response element 2 changes history +2,239 [Marshallsumter (2×)] | |||
| m |
|
20:03 (cur | prev) +608 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:34 (cur | prev) +1,631 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:32 | User creation log User account Jonathan Reyes talk contribs was created by Alberto Castro Molina talk contribs | ||||
| 04:27 | Daprodustat diffhist +1,079 Alen Antony talk contribs | ||||
25 April 2024
| 22:53 | Reni Syndrome diffhist −3 Alara E. Dagsali talk contribs | ||||
|
|
N 22:52 | User:AED 3 changes history +3,204 [Alara E. Dagsali (3×)] | |||
|
|
22:52 (cur | prev) −144 Alara E. Dagsali talk contribs | ||||
|
|
22:51 (cur | prev) +407 Alara E. Dagsali talk contribs | ||||
| N |
|
22:39 (cur | prev) +2,941 Alara E. Dagsali talk contribs (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...") | |||
| 22:48 | Adagrasib diffhist +3 Alara E. Dagsali talk contribs | ||||
| 22:45 | Norelgestromin diffhist +3 Alara E. Dagsali talk contribs | ||||
|
|
22:45 | Tranexamic 6 changes history +1 [Alara E. Dagsali (6×)] | |||
|
|
22:45 (cur | prev) +11 Alara E. Dagsali talk contribs | ||||
|
|
22:44 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
|
22:41 (cur | prev) +2 Alara E. Dagsali talk contribs | ||||
|
|
22:41 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
|
22:40 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
22:39 (cur | prev) −14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
| 22:36 | Alara E. Dagsali diffhist +40 Alara E. Dagsali talk contribs | ||||
|
|
N 21:21 | Daprodustat 6 changes history +6,894 [Alen Antony (6×)] | |||
|
|
21:21 (cur | prev) +952 Alen Antony talk contribs | ||||
|
|
20:53 (cur | prev) +1,266 Alen Antony talk contribs | ||||
|
|
19:07 (cur | prev) +2,809 Alen Antony talk contribs | ||||
|
|
17:23 (cur | prev) +563 Alen Antony talk contribs | ||||
|
|
16:47 (cur | prev) +147 Alen Antony talk contribs | ||||
| N |
|
15:23 (cur | prev) +1,157 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...") | |||
|
|
m 17:37 | Non-degenerate nucleotides per response element 2 changes history +3,020 [Marshallsumter (2×)] | |||
| m |
|
17:37 (cur | prev) +705 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:56 (cur | prev) +2,315 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:03 | Chronic hypertension medical therapy diffhist +715 Badgettrg talk contribs (→Impact of Blood Pressure self-monitoring in Hypertension Control) | ||||
|
|
01:50 | Bexagliflozin 4 changes history +3,949 [Alen Antony (4×)] | |||
|
|
01:50 (cur | prev) +1,145 Alen Antony talk contribs | ||||
|
|
00:57 (cur | prev) +669 Alen Antony talk contribs | ||||
|
|
00:50 (cur | prev) +1,349 Alen Antony talk contribs | ||||
|
|
00:17 (cur | prev) +786 Alen Antony talk contribs | ||||
24 April 2024
|
|
N 23:35 | Bexagliflozin 4 changes history +1,938 [Alen Antony (4×)] | |||
|
|
23:35 (cur | prev) +245 Alen Antony talk contribs | ||||
|
|
23:11 (cur | prev) +1,453 Alen Antony talk contribs | ||||
|
|
22:55 (cur | prev) +164 Alen Antony talk contribs | ||||
| N |
|
21:06 (cur | prev) +76 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}") | |||
| 23:17 | Endocarditis overview diffhist +5,051 Kosar Doraghi talk contribs | ||||
|
|
23:04 | (Upload log) [Kosar Doraghi (2×)] | |||
|
|
23:04 Kosar Doraghi talk contribs uploaded File:IMG 1177.jpeg | ||||
|
|
22:59 Kosar Doraghi talk contribs uploaded File:IMG 1176.jpeg | ||||
|
|
m 23:02 | Non-degenerate nucleotides per response element 4 changes history +4,215 [Marshallsumter (4×)] | |||
| m |
|
23:02 (cur | prev) +2,787 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
19:16 (cur | prev) +570 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
06:39 (cur | prev) +506 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
04:26 (cur | prev) +352 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
N 21:26 | Tranexamic 7 changes history +23,022 [Alara E. Dagsali (7×)] | |||
|
|
21:26 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
21:26 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
|
21:25 (cur | prev) −2 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
21:23 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
|
21:23 (cur | prev) +3 Alara E. Dagsali talk contribs Tag: Visual edit: Switched | ||||
|
|
21:22 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
| N |
|
21:14 (cur | prev) +23,020 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...") | |||
|
|
N 21:25 | Template:AlaraE.Dagsali 2 changes history +74 [Alara E. Dagsali (2×)] | |||
|
|
21:25 (cur | prev) −14 Alara E. Dagsali talk contribs | ||||
| N |
|
21:21 (cur | prev) +88 Alara E. Dagsali talk contribs (Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]") | |||
| 18:12 | Hospital readmissions diffhist +640 Badgettrg talk contribs (→Adults) | ||||
|
|
07:55 | SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY 2 changes history +2,023 [Hafiza Amna Qadeer (2×)] | |||
|
|
07:55 (cur | prev) +965 Hafiza Amna Qadeer talk contribs | ||||
|
|
07:52 (cur | prev) +1,058 Hafiza Amna Qadeer talk contribs (added clinical features) Tag: Visual edit | ||||
23 April 2024
|
|
m 20:09 | Non-degenerate nucleotides per response element 2 changes history +1,082 [Marshallsumter (2×)] | |||
| m |
|
20:09 (cur | prev) +108 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
09:01 (cur | prev) +974 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 15:32 | User creation log User account Malaika Hassan talk contribs was created by Alberto Castro Molina talk contribs | ||||
22 April 2024
|
|
m 20:10 | Non-degenerate nucleotides per response element 2 changes history +204 [Marshallsumter (2×)] | |||
| m |
|
20:10 (cur | prev) +153 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
09:11 (cur | prev) +51 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
18:44 | (Upload log) [Alara E. Dagsali (2×)] | |||
|
|
18:44 Alara E. Dagsali talk contribs uploaded File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg | ||||
|
|
18:43 Alara E. Dagsali talk contribs uploaded File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG | ||||
21 April 2024
|
|
m 22:07 | Non-degenerate nucleotides per response element 4 changes history +3,558 [Marshallsumter (4×)] | |||
| m |
|
22:07 (cur | prev) +11 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
21:47 (cur | prev) +817 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:02 (cur | prev) +405 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
03:31 (cur | prev) +2,325 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
N 04:03 | BRENZAVVY- bexagliflozin 2 changes history +12,281 [Kosar Doraghi (2×)] | |||
|
|
04:03 (cur | prev) +198 Kosar Doraghi talk contribs | ||||
| N |
|
03:47 (cur | prev) +12,083 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...") | |||
|
|
03:48 | (Upload log) [Kosar Doraghi (4×)] | |||
|
|
03:48 Kosar Doraghi talk contribs uploaded File:IMG 1052.jpeg | ||||
|
|
03:43 Kosar Doraghi talk contribs uploaded File:IMG 1050.jpeg | ||||
|
|
03:40 Kosar Doraghi talk contribs uploaded File:IMG 1051.jpeg | ||||
|
|
03:34 Kosar Doraghi talk contribs uploaded File:IMG 1049.jpeg | ||||
20 April 2024
|
|
23:33 | User:Imam Ali Shah 6 changes history 0 [Imam Ali Shah (6×)] | |||
|
|
23:33 (cur | prev) −184 Imam Ali Shah talk contribs (→adada) Tag: Manual revert | ||||
|
|
23:33 (cur | prev) +184 Imam Ali Shah talk contribs Tag: Visual edit: Switched | ||||
|
|
23:31 (cur | prev) −964 Imam Ali Shah talk contribs (→jahdijahjdh) Tag: Manual revert | ||||
|
|
23:31 (cur | prev) +964 Imam Ali Shah talk contribs (→Communication Languages) | ||||
|
|
23:26 (cur | prev) −5,843 Imam Ali Shah talk contribs Tags: Manual revert Visual edit: Switched | ||||
|
|
23:24 (cur | prev) +5,843 Imam Ali Shah talk contribs | ||||
|
|
m 20:03 | Non-degenerate nucleotides per response element 2 changes history +255 [Marshallsumter (2×)] | |||
| m |
|
20:03 (cur | prev) +51 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:14 (cur | prev) +204 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m 17:23 | H box gene transcriptions diffhist 0 Marshallsumter talk contribs (→H box (Mitchell) consensus sequences) | ||||
|
|
N 16:19 | Template:IAS 3 changes history +75 [Imam Ali Shah (3×)] | |||
|
|
16:19 (cur | prev) −33 Imam Ali Shah talk contribs | ||||
|
|
16:11 (cur | prev) +19 Imam Ali Shah talk contribs | ||||
| N |
|
16:05 (cur | prev) +89 Imam Ali Shah talk contribs (Created page with "Associate Editor-In-Chief: Imam Ali Shah, MBBS; Chandka Medical College, Larkana Pakistan") | |||
| 03:21 | User:Edzelco diffhist +31 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| 03:20 | Cipaglucosidase alfa-atga diffhist +38,269 Edzelco talk contribs | ||||
19 April 2024
|
|
m 21:06 | Non-degenerate nucleotides per response element 4 changes history −3,707 [Marshallsumter (4×)] | |||
| m |
|
21:06 (cur | prev) +757 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
19:50 (cur | prev) −5,407 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:50 (cur | prev) +779 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
01:58 (cur | prev) +164 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
20:03 | Template:KDRG 2 changes history +60 [Kosar Doraghi (2×)] | |||
|
|
20:03 (cur | prev) +129 Kosar Doraghi talk contribs | ||||
|
|
19:53 (cur | prev) −69 Kosar Doraghi talk contribs | ||||
| N 16:30 | Sparsentan diffhist +8,644 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...") | ||||
|
|
16:24 | (Upload log) [Kosar Doraghi (4×)] | |||
|
|
16:24 Kosar Doraghi talk contribs uploaded File:IMG 1046.jpeg | ||||
|
|
16:14 Kosar Doraghi talk contribs uploaded File:IMG 1045.jpeg | ||||
|
|
16:11 Kosar Doraghi talk contribs uploaded File:IMG 1047.jpeg | ||||
|
|
16:05 Kosar Doraghi talk contribs uploaded File:IMG 1044.jpeg | ||||
| 16:17 | Somatic symptom disorder diffhist +485 Badgettrg talk contribs (→Treatment) | ||||
18 April 2024
|
|
m 22:49 | Non-degenerate nucleotides per response element 4 changes history +2,760 [Marshallsumter (4×)] | |||
| m |
|
22:49 (cur | prev) +564 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
20:37 (cur | prev) +1,206 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:39 (cur | prev) +727 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
04:35 (cur | prev) +263 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
m 18:29 | Xenobiotic response element gene transcriptions 2 changes history +93 [Marshallsumter (2×)] | |||
| m |
|
18:29 (cur | prev) +29 Marshallsumter talk contribs (→QRDRE analysis and results) | |||
| m |
|
18:27 (cur | prev) +64 Marshallsumter talk contribs (→QRDRE analysis and results) | |||
| 12:48 | User:Edzelco diffhist +96 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
12:45 | Momelotinib 2 changes history +34,070 [Edzelco (2×)] | |||
|
|
12:45 (cur | prev) −220 Edzelco talk contribs | ||||
|
|
12:44 (cur | prev) +34,290 Edzelco talk contribs | ||||
| 12:12 | Motixafortide diffhist +26,053 Edzelco talk contribs | ||||
| 11:49 | Pozelimab-bbfg diffhist +2,390 Edzelco talk contribs | ||||
| 11:42 | Palovarotene diffhist +39,181 Edzelco talk contribs | ||||
| 11:16 | Elranatamab-bcmm diffhist +32,847 Edzelco talk contribs | ||||
| 06:18 | Endocarditis overview diffhist +2,588 Kosar Doraghi talk contribs | ||||
17 April 2024
|
|
N 20:47 | SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY 3 changes history +364 [Hafiza Amna Qadeer (3×)] | |||
|
|
20:47 (cur | prev) −13 Hafiza Amna Qadeer talk contribs (minor edit) Tag: Visual edit | ||||
|
|
20:46 (cur | prev) +377 Hafiza Amna Qadeer talk contribs (new page minor edit) Tag: Visual edit | ||||
| N |
|
19:33 (cur | prev) 0 Hafiza Amna Qadeer talk contribs (Created blank page) | |||
|
|
m 18:11 | Non-degenerate nucleotides per response element 2 changes history +601 [Marshallsumter (2×)] | |||
| m |
|
18:11 (cur | prev) +438 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
06:52 (cur | prev) +163 Marshallsumter talk contribs (→Tabulation of counts) | |||
| N 08:08 | Elranatamab-bcmm diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:08 | Palovarotene diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:08 | Pozelimab-bbfg diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:07 | Motixafortide diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:07 | Momelotinib diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:06 | Cipaglucosidase alfa-atga diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:05 | Etrasimod diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:05 | Zilucoplan diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Bimekizumab diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Vamorolone diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Mirikizumab-mrkz diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:03 | Toripalimab-tpzi diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
|
|
08:02 | User:Edzelco 5 changes history +99 [Edzelco (5×)] | |||
|
|
08:02 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:53 (cur | prev) +26 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:44 (cur | prev) 0 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:44 (cur | prev) +36 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:43 (cur | prev) +19 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 08:02 | Fruquintinib diffhist +25,648 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...") | ||||
|
|
N 07:53 | Taurolidine, heparin 2 changes history +9,993 [Edzelco (2×)] | |||
|
|
07:53 (cur | prev) 0 Edzelco talk contribs | ||||
| N |
|
07:52 (cur | prev) +9,993 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...") | |||
| N 07:43 | Repotrectinib diffhist +32,783 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...") | ||||
|
|
N 07:34 | Efbemalenograstim alfa-vuxw 3 changes history +20,126 [Edzelco (3×)] | |||
|
|
07:34 (cur | prev) 0 Edzelco talk contribs | ||||
|
|
07:33 (cur | prev) +51 Edzelco talk contribs | ||||
| N |
|
07:32 (cur | prev) +20,075 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....") | |||
| 04:20 | Endocarditis overview diffhist +9,001 Kosar Doraghi talk contribs | ||||
16 April 2024
|
|
m 17:29 | Non-degenerate nucleotides per response element 2 changes history +606 [Marshallsumter (2×)] | |||
| m |
|
17:29 (cur | prev) +201 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:14 (cur | prev) +405 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
15:06 | Trismus 3 changes history +1,038 [M. Arsalan Bashir (3×)] | |||
|
|
15:06 (cur | prev) 0 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
|
15:00 (cur | prev) +223 M. Arsalan Bashir talk contribs | ||||
|
|
13:30 (cur | prev) +815 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
|
05:50 | User:Edzelco 2 changes history +33 [Edzelco (2×)] | |||
|
|
05:50 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
05:28 (cur | prev) +15 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 05:50 | Capivasertib diffhist +34,175 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...") | ||||
| N 05:27 | Iptacopan diffhist +33,311 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...") | ||||
| 01:37 | Birch triterpenes diffhist +1,569 Rafael Garcia talk contribs | ||||
15 April 2024
|
|
m 20:06 | Non-degenerate nucleotides per response element 2 changes history +1,954 [Marshallsumter (2×)] | |||
| m |
|
20:06 (cur | prev) +875 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:42 (cur | prev) +1,079 Marshallsumter talk contribs | |||
| 18:43 | Hand contracture diffhist −11 Dj talk contribs | ||||
| 07:25 | User:Edzelco diffhist +16 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 07:24 | Vutrisiran diffhist +17,228 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...") | ||||
14 April 2024
|
|
m 20:07 | Non-degenerate nucleotides per response element 3 changes history +2,087 [Marshallsumter (3×)] | |||
| m |
|
20:07 (cur | prev) +100 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
17:58 (cur | prev) +512 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:09 (cur | prev) +1,475 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:41 | Somatic symptom disorder diffhist +992 Badgettrg talk contribs (→Overview) | ||||
| 14:19 | Systematic review diffhist +554 Badgettrg talk contribs (→Meta-narrative reviews) | ||||